Squarepoint’s Altamira Therapeutics Ltd CYTO Stock Holding History

Squarepoint’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25	Closed	-$36K	–	3597
2021 Q2	$36K	Buy	+25	New	+$34.3K	﹤0.01%	3127

Other funds holding CYTO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's CYTO Position: Q3 2021 in Review

Squarepoint sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2021, closing a stake of 25 shares — an estimated $36K sold.

Squarepoint first reported a position in CYTO in Q2 2021 and held it in 1 quarter. The position peaked at $36K in Q2 2021. 15 funds tracked by Wall St. Rank hold CYTO as of Q3 2021.

Squarepoint reported no remaining Altamira Therapeutics Ltd position as of Q3 2021 after selling out during the quarter.
Squarepoint sold 25 Altamira Therapeutics Ltd shares in Q3 2021, an estimated $36K.
Squarepoint first reported a position in Altamira Therapeutics Ltd in Q2 2021 and held it in 1 quarter.
Squarepoint's Altamira Therapeutics Ltd position peaked at $36K in Q2 2021.
15 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.